Prospects for the Use of ATR Inhibitors to Treat Cancer

Pharmaceuticals

Jill M. Wagner¹ 

[1] Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA; E-Mail

关键词: Replication checkpoint;    ATR;    ATM;    chemotherapy;    Chk1;   

DOI  :  10.3390/ph3051311

来源: mdpi

【 摘 要 】

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.